Hospitalizations

• 最近的一项研究表明，在过去的一个季节中，更新的疫苗配方使健康成年人的急诊就诊量和住院率降低了约 50%。 • 这一显著的有效性提升代表了疫苗研发和公共卫生防护策略的一次重大进步。 • 这些发现为美国不断演变的疫苗政策格局提供了支持，具体可见于 CIDRAP 2026 年 4 月 28 日发布的最新疫苗政策状态报告。

• The U.S. daily COVID-19 case average increased by 13.3% over the past week, though hospitalizations continue to decline according to federal data. • About 48,000 patients are currently hospitalized with COVID-19, representing a decrease of nearly 104,000 patients over the past eight weeks, with hospital admissions down 11.7% weekly. • Alaska has the highest infection rate in the nation, followed by Montana, North Dakota, and Wyoming, while Puerto Rico, Florida, and Hawaii report the lowest rates.

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.